BioCryst Pharmaceuticals (BCRX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for BioCryst Pharmaceuticals (NASDAQ: BCRX):

• 11/5/2025 – BioCryst Pharmaceuticals had its price target lowered by analysts at Citizens Jmp from $27.00 to $25.00. They now have a “market outperform” rating on the stock.
• 11/4/2025 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/4/2025 – BioCryst Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $11.00 to $9.00. They now have an “equal weight” rating on the stock.
• 11/4/2025 – BioCryst Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a “buy” rating on the stock.
• 10/15/2025 – BioCryst Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $24.00 to $26.00. They now have an “overweight” rating on the stock.
• 10/15/2025 – BioCryst Pharmaceuticals is now covered by analysts at TD Cowen. They set a “buy” rating and a $30.00 price target on the stock.
• 10/15/2025 – BioCryst Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $17.00 to $20.00. They now have a “buy” rating on the stock.
• 10/15/2025 – BioCryst Pharmaceuticals had its price target raised by analysts at JMP Securities from $17.00 to $27.00. They now have a “market outperform” rating on the stock.
• 10/8/2025 – BioCryst Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – BioCryst Pharmaceuticals was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/1/2025 – BioCryst Pharmaceuticals had its “in-line” rating reaffirmed by analysts at Evercore ISI. They now have a $8.00 price target on the stock.
• 9/27/2025 – BioCryst Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.